{"id":"NCT03692871","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)","officialTitle":"A Phase 3, Multicenter, Randomized, Double-blind, Active Comparator-controlled Study to Evaluate the Safety and Tolerability of V114 in Healthy Infants (PNEU-LINK)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-12-14","primaryCompletion":"2021-03-26","completion":"2021-03-26","firstPosted":"2018-10-02","resultsPosted":"2022-05-10","lastUpdate":"2023-07-28"},"enrollment":2409,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"PREVENTION"},"conditions":["Pneumococcal Infections"],"interventions":[{"type":"BIOLOGICAL","name":"V114","otherNames":["VAXNEUVANCE™","Pneumococcal 15-Valent Conjugate Vaccine"]},{"type":"BIOLOGICAL","name":"Prevnar 13™","otherNames":[]}],"arms":[{"label":"V114","type":"EXPERIMENTAL"},{"label":"Prevnar 13™","type":"ACTIVE_COMPARATOR"}],"summary":"This study is designed to evaluate the safety and tolerability of V114 and Prevnar 13™ in healthy infants. This study will include both full-term infants (≥37 weeks gestational age) and premature infants (\\<37 weeks gestational age). Premature infants will be included in a Premature Infant Immunogenicity Substudy, which will assess immunogenicity and safety following administration of V114 or Prevnar 13™.","primaryOutcome":{"measure":"Percentage of Participants With a Solicited Injection-site Adverse Event","timeFrame":"Up to Day 14 after each study vaccination","effectByArm":[{"arm":"V114","deltaMin":43.9,"sd":null},{"arm":"Prevnar 13™","deltaMin":36,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"= 0.003"},{"comp":"OG000 vs OG001","p":"= 0.882"},{"comp":"OG000 vs OG001","p":"= 0.014"},{"comp":"OG000 vs OG001","p":"= 0.051"}]},"eligibility":{"minAge":"42 Days","sex":"ALL","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":15},"locations":{"siteCount":76,"countries":["United States","Australia","Canada","Finland","Germany","Israel","Malaysia","Peru","Taiwan","Thailand"]},"refs":{"pmids":["37309607"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":192,"n":1965},"commonTop":["Irritability","Somnolence","Injection site erythema","Injection site pain","Decreased appetite"]}}